Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5821-5830

  Hall, Belinda S ^a,b   Meredith, Emma Louise ^a   Wilkinson, Shane R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTITRYPANOSOMAL AGENT; AZIRIDINYLBENZOQUINONE; BENZNIDAZOLE; DUROQUINONE; METRONIDAZOLE; NIFURTIMOX; NITROBENZYLTHIOGUANOSINE; NITROFURAL; NITROFURANTOIN; NITROREDUCTASE; PRODRUG; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINONE;

ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME SUBSTRATE; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

BENZOQUINONES; ESCHERICHIA COLI; KINETICS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NAD; NIFURTIMOX; NITROIMIDAZOLES; NITROREDUCTASES; PRODRUGS; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI;

EID: 84868019328     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01227-12     Document Type: Article

References (68)

1. Alsford S, et al. 2012. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482:232-236.
2. Alsford S, Kawahara T, Glover L, Horn D. 2005. Tagging a T. brucei rRNA locus improves stable transfection efficiency and circumvents in-ducible expression position effects. Mol. Biochem. Parasitol. 144:142-148.
3. Armstrong JM. 1964. The molar extinction coefficient of 2,6-dichlorophenol indophenol. Biochim. Biophy. Acta 86:194-197.
4. Begleiter A. 2000. Clinical applications of quinone-containing alkylating agents. Front. Biosci. 5:E153-E171.
5. Bern C, Montgomery SP. 2009. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49:e52-e54.
6. Bienen EJ, Maturi RK, Pollakis G, Clarkson AB, Jr. 1993. Non-cytochrome mediated mitochondrial ATP production in bloodstream form Trypanosoma brucei brucei. Eur. J. Biochem. 216:75-80.
7. Bot C, et al. 2010. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 54:4246-4252.
8. Brun R, Blum J, Chappuis F, Burri C. 2010. Human African trypano-somiasis. Lancet 375:148-159.
9. Bryant C, DeLuca M. 1991. Purification and characterization of an oxygen-insensitive NAD(P)H nitroreductase from Enterobacter cloacae. J. Biol. Chem. 266:4119-4125.
10. Chaudhuri M, Ott RD, Hill GC. 2006. Trypanosome alternative oxidase: from molecule to function. Trends Parasitol. 22:484-491.
11. Chen Y, Hu L. 2009. Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 29:29-64.
12. Clarkson AB, Jr, Bienen EJ, Pollakis G, Grady RW. 1989. Respiration of bloodstream forms of the parasiteTrypanosoma brucei brucei is dependent on a plant-like alternative oxidase. J. Biol. Chem. 264:17770-17776.
13. Danson S, Ranson M, Denneny O, Cummings J, Ward TH. 2007. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Cancer Chemother. Pharmacol. 60:851-861.
14. Danson SJ, et al. 2011. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann. Oncol. 22:1653-1660.
15. Ernster L, Danielson L, Ljunggren M. 1962. DT diaphorase. I. Purification from the soluble fraction of rat-liver cytoplasm, and properties. Biochim. Biophys. Acta 58:171-188.
16. Faeder EJ, Siegel LM. 1973. A rapid micromethod for determination of FMN and FAD in mixtures. Anal. Biochem. 53:332-336.
17. Fang J, Beattie DS. 2003. Identification of a gene encoding a 54 kDa alternative NADH dehydrogenase in Trypanosoma brucei. Mol. Biochem. Parasitol. 127:73-77.
18. Fang J, Beattie DS. 2002. Novel FMN-containing rotenone-insensitive NADH dehydrogenase from Trypanosoma brucei mitochondria: isolation and characterization. Biochemistry 41:3065-3072.
19. Fang J, Beattie DS. 2002. Rotenone-insensitive NADH dehydrogenase is a potential source of superoxide in procyclic Trypanosoma brucei mitochondria. Mol. Biochem. Parasitol. 123:135-142.
20. Fang J, Wang Y, Beattie DS. 2001. Isolation and characterization of complex I, rotenone-sensitive NADH: ubiquinone oxidoreductase, from the procyclic forms of Trypanosoma brucei. Eur. J. Biochem. 268:3075-3082.
21. Garavaglia PA, et al. 2010. Identification, cloning and characterization of an aldo-keto reductase from Trypanosoma cruzi with quinone oxidoreductase activity. Mol. Biochem. Parasitol. 173:132-141.
22. Gascon J, Bern C, Pinazo MJ. 2009. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 115:22-27.
23. Gautret P, et al for EuroTravNet. 2009. Imported human African trypanosomiasis in Europe, 2005-2009. Euro. Surveill. 14: pii=19327. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19327.
24. Goodwin A, et al. 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:383-393.
25. Guerra DG, Decottignies A, Bakker BM, Michels PA. 2006. The mitochondrial FAD-dependent glycerol-3-phosphate dehydrogenase of Trypanosomatidae and the glycosomal redox balance of insect stages of Trypanosoma brucei and Leishmania spp. Mol. Biochem. Parasitol. 149: 155-169.
26. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation by trypano-somal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286:13088-13095.
27. Hall BS, Wilkinson SR. 2012. Activation of benznidazole by trypano-somal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 56:115-123.
28. Hall BS, Wu X, Hu L, Wilkinson SR. 2010. Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 54:1193-1199.
29. Henderson GB, et al. 1988. "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc. Natl. Acad. Sci. U. S. A. 85:5374-5378.
30. Hirumi H, Hirumi K. 1989. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989.
31. Hoet S, Opperdoes F, Brun R, Quetin-Leclercq J. 2004. Natural products active against African trypanosomes: a step towards new drugs. Nat. Prod. Rep. 21:353-364.
32. Hu LQ, et al. 2011. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorg. Med. Chem. Lett. 21:3986-3991.
33. Iyanagi T, Yamazaki I. 1970. One-electron-transfer reactions in biochemical systems. V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim. Biophys. Acta 216:282-294.
34. Jaiswal AK. 2000. Regulation of genes encoding NAD(P)H: quinone oxi-doreductases. Free Radic. Biol. Med. 29:254-262.
35. Jarrom D, et al. 2009. Steady-state and stoppedflow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954. Biochemistry 48:7665-7672.
36. Koder RL, Miller AF. 1998. Steady-state kinetic mechanism, stereospec-ificity, substrate and inhibitor specificity of Enterobacter cloacae nitroreductase. Biochim. Biophys. Acta 1387:395-405.
37. Kubata BK, et al. 2002. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med. 196:1241-1251.
38. Müller J, Wastling J, Sanderson S, Muller N, Hemphill A. 2007. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother. 51:1979-1986.
39. Nillius D, Muller J, Muller N. 2011. Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. J. Antimicrob. Chemother. 66:1029-1035.
40. Nivinskas H, et al. 2002. Two-electron reduction of quinones by Entero-bacter cloacae NAD(P)H: nitroreductase: quantitative structure-activity relationships. Arch. Biochem. Biophys. 403:249-258.
41. Nixon JE, et al. 2002. Evidence for lateral transfer of genes encoding ferredoxins, nitroreductases, NADH oxidase, and alcohol dehydrogenase 3 from anaerobic prokaryotes to Giardia lamblia and Entamoeba histolytica. Eukaryot. Cell 1:181-190.
42. O'Brien PJ. 1991. Molecular mechanisms of quinone cytotoxicity. Chem.-Biol. Interact. 80:1-41.
43. Pal D, et al. 2009. Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob. Agents Chemother. 53:458-464.
44. Parkinson GN, Skelly JV, Neidle S. 2000. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J. Med. Chem. 43:3624-3631.
45. Peterson FJ, Mason RP, Hovsepian J, Holtzman JL. 1979. Oxygen-sensitive and -insensitive nitroreduction byEscherichia coli and rat hepatic microsomes. J. Biol. Chem. 254:4009-4014.
46. Pinto AV, de Castro SL. 2009. The trypanocidal activity of naphthoqui-nones: a review. Molecules 14:4570-4590.
47. Powis G. 1989. Free radical formation by antitumor quinones. Free Rad. Biol. Med. 6:63-101.
48. Purkayastha A, McCue LA, McDonough KA. 2002. Identification of a Mycobacterium tuberculosis putative classical nitroreductase gene whose expression is coregulated with that of the acr aene within macrophages, in standing versus shaking cultures, and under low oxygen conditions. Infect. Immun. 70:1518-1529.
49. Race PR, et al. 2005. Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone. Reversed binding orientations in different redox states of the enzyme. J. Biol. Chem. 280:13256-13264.
50. Race PR, et al. 2007. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J. Mol. Biol. 368:481-492.
51. Ramos EI, et al. 2009. 2,3-Diphenyl-1,4-naphthoquinone: a potential chemotherapeutic agent against Trypanosoma cruzi. J. Parasitol. 95:461-466.
52. Rassi A, Marin-Neto JA. 2010. Chagas disease. Lancet 375:1388-1402.
53. Stein DC, Carrizosa E, Dunham S. 2009. Use of nfsB, encoding nitrore-ductase, as a reporter gene to determine the mutational spectrum of spontaneous mutations in Neisseria gonorrhoeae. BMC Microbiol. 9:239. doi: 10.1186/1471-2180-9-239.
54. Stuart K, et al. 2008. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest. 118:1301-1310.
55. Surve S, Heestand M, Panicucci B, Schnaufer A, Parsons M. 2012. Enigmatic presence of mitochondrial complex I in Trypanosoma brucei bloodstream forms. Eukaryot. Cell 11:183-193.
56. Tatsumi K, et al. 1981. Studies on oxygen-insensitive nitrofuran reduc-tase in Escherichia coli B/r. J. Biochem. 89:855-859.
57. Tedeschi G, Chen S, Massey V. 1995. Active site studies of DT-diaphorase employing artificial flavins. J. Biol. Chem. 270:2512-2516.
58. Torri AF, Bertrand KI, Hajduk SL. 1993. Protein stability regulates the expression of cytochrome c during the developmental cycle of Trypanosoma brucei. Mol. Biochem. Parasitol. 57:305-315.
59. Torri AF, Hajduk SL. 1988. Posttranscriptional regulation of cytochrome c expression during the developmental cycle of Trypanosoma brucei. Mol. Cell. Biol. 8:4625-4633.
60. Urech K, Neumayr A, Blum J. 2011. Sleeping sickness in travelers - do they really sleep? PLoS Negl. Trop. Dis. 5:e1358. doi:10.1371/journal.pntd. 0001358.
61. Ward TH, et al. 2005. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone. Clin. Cancer Res. 11:2695-2701.
62. Watanabe M, Nishino T, Takio K, Sofuni T, Nohmi T. 1998. Purification and characterization of wild-type and mutant "classical" nitroreduc-tases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J. Biol. Chem. 273: 23922-23928.
63. Whiteway J, et al. 1998. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J. Bacteriol. 180:5529-5539.
64. Wilkinson SR, Kelly JM. 2009. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Mol. Med. 11:e31. http://dx.doi.org/10.1017/ S1462399409001252.
65. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in try-panosomes. Proc. Natl. Acad. Sci. U. S. A. 105:5022-5027.
66. Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D. 2008. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol. Pharmacol. 74:1657-1665.
67. Zenno S, et al. 1996. Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J. Bacteriol. 178: 4508-4514.
68. Zenno S, Koike H, Tanokura M, Saigo K. 1996. Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J. Biochem. 120:736-744.